Puerto Rico is among a select group of U.S. jurisdictions specializing in four of the five sectors that make up the thriving bioscience industry and is among a handful of states boasting a significant employment base and a specialized concentration of jobs in drugs and pharmaceuticals, according to the findings of the “Battelle/BIO State Bioscience Industry Development Report” released Wednesday.
Puerto Rico Puerto, the second largest investment destination in the region, is struggling to retain its position as a “viable value proposition” for pharmaceutical companies that have significantly scaled back their investments on the island in the last four years, a recently released study by Jones Lang LaSalle a global real estate services firm concluded.
The Puerto Rico Manufacturers Association rejected the conclusions of a study released this week language and cultural barriers among the employees in companies located in Puerto Rico and their stateside counterparts may be risk factors causing quality problems in local plants.
A Dow Jones/Factiva content provider since 2014
Subscribe to our Dollars & Sense podcast!
